A5045479916- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Gallbladder and Bile Duct Disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Melanoma and MAPK Pathways
- Blood Coagulation and Thrombosis Mechanisms
- Cancer Treatment and Pharmacology
- Cancer, Lipids, and Metabolism
- Palliative Care and End-of-Life Issues
- Hepatitis B Virus Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Lung Cancer Research Studies
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
- Synthesis and biological activity
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Frailty in Older Adults
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
Azienda Ospedaliera Universitaria Pisana
2020-2024
University of Pisa
2020-2024
University of Rome Tor Vergata
2024
University of Southern California
2012
Background: There are currently few data about the safety and effectiveness of chemotherapy for patients with metastatic non-small-cell lung cancer (NSCLC) who have progressed from prior immunotherapy. Methods: Data consecutive stage IIIB-IV, ECOG performance status (PS) 0-2, treated combination or single-agent following progression on an earlier immunotherapy regimen were retrospectively gathered. Recorded baseline attributes, outcome metrics, toxicities. The neutrophil/lymphocyte (N/L)...
<b><i>Background and Aims:</i></b> In the last few years, there has been increasing interest in non-cancer medications their potential anti-cancer activity. Data are not available cholangiocarcinoma (CCA) patients. The aim of this study is to fill gap by investigating impact terms clinical outcome common medications. <b><i>Methods:</i></b> All consecutive patients with CCAs were retrospectively identified from 7 Italian medical institutions. We...
Abstract Background and Aims The best adjuvant chemotherapy for resected biliary tract cancer (BTC) is under debate, with capecitabine supported by weak evidence. Aim of this network meta‐analysis to estimate the efficacy different phase II/III regimens, comparing monotherapies (gemcitabine or fluoropyrimidines) head‐to‐head, against observation combination regimens. Methods A comprehensive literature search was conducted on PubMed EMBASE randomized clinical trials (RCTs) available as...
Objective: This study aimed to compare robotic pancreatoduodenectomy with vein resection (PD-VR) based on the incidence of severe postoperative complications (SPC). Background: Robotic has been gaining momentum in recent years. Vein is frequently required this operation, but no compared and open PD-VR using a matched analysis. Methods: was an intention-to-treat designed demonstrate noninferiority (2011–2021) SPC. To achieve power 80% (noninferiority margin:10%; α error: 0.05; ß 0.20), 1:1...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, with most patients diagnosed at advanced stages. First-line treatment based on a combined chemotherapy (FOLFIRINOX or gemcitabine plus nab-paclitaxel) provides limited benefits. Olaparib, PARP inhibitor, has been approved as maintenance for PDAC harboring germline BRCA1/2 pathogenic mutations and previously treated platinum-based chemotherapy. testing recommended, but also somatic could predict responses to inhibitors. Analysis...
Mismatch repair (MMR) deficiency represents a biomarker and therapeutic target in various neoplasms, but its role biliary tract cancers (BTCs) remains misunderstood.
We retrospectively evaluated the effect of dabrafenib/trametinib combination in patients with BRAF-mutated non-small-cell lung cancer (NSCLC) treated a single center from 2017 to 2022.
e16068 Background: Peritoneum represents one of the most common metastatic sites gastroesophageal adenocarcinoma (GEA) and is associated with poor prognosis. Programmed death-ligand 1 (PD-L1) expression a recognized predictive biomarker response to immune checkpoint inhibitors (ICIs) in first-line setting. However, data from pivotal trials showed poorer clinical efficacy ICIs sub-set patients peritoneal involvement, regardless PD-L1 score magnitude. Here, we investigated temporal spatial...
Background: Understanding the specific needs of cancer survivors is essential for healthcare policy. In Italy, dedicated studies are lacking, so we aimed to investigate physical, mental, social, and health difficulties encountered by these patients. Methods: We conducted a cross-sectional study on breast or colorectal (people 5+ years free from it its treatments) using an ad hoc survey including validated questionnaires (Grauer–Palombi, SF-36, PREDIMED). Participants were recruited within...
FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GN) are the most common chemotherapy regimens in first-line treatment of metastatic pancreatic cancer (PC). They have not been compared each other a prospective trial, but only retrospective studies, which can thus be affected by several biases. In order to overcome these biases, we took advantage matching-adjusted indirect comparison (MAIC), that allows an reducing cross-trial differences, data from 268 patients treated with GN real-world...